Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.

Ther Adv Respir Dis · 2018 · PMC6156214 · PMID 30249169

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

FVC decline in patients receiving highest dose nintedanib (150 mg twice daily) was lower compared with patients receiving placebo (0.06 l versus 0.19 l) however failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.